Gilder Gagnon Howe & Co. LLC Acquires 41,030 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Gilder Gagnon Howe & Co. LLC boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 361.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,379 shares of the company's stock after purchasing an additional 41,030 shares during the period. Gilder Gagnon Howe & Co. LLC owned 0.10% of Janux Therapeutics worth $2,804,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JANX. Russell Investments Group Ltd. boosted its position in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after purchasing an additional 442 shares in the last quarter. Avanza Fonder AB purchased a new position in Janux Therapeutics in the fourth quarter valued at about $139,000. Meeder Asset Management Inc. bought a new position in Janux Therapeutics during the fourth quarter worth about $159,000. Tower Research Capital LLC TRC raised its stake in shares of Janux Therapeutics by 878.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock valued at $205,000 after purchasing an additional 3,436 shares during the period. Finally, Chicago Capital LLC purchased a new position in shares of Janux Therapeutics during the 4th quarter valued at $230,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

JANX has been the topic of several research reports. Wedbush reissued an "outperform" rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. Finally, Scotiabank dropped their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $95.25.

Janux Therapeutics Price Performance

Janux Therapeutics stock traded up $1.62 during mid-day trading on Friday, hitting $33.67. 404,350 shares of the company were exchanged, compared to its average volume of 847,742. The company has a market capitalization of $1.99 billion, a P/E ratio of -28.82 and a beta of 3.27. Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71. The business's 50 day simple moving average is $29.80 and its two-hundred day simple moving average is $42.70.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 341,742 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was purchased at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the purchase, the director now owns 9,658,988 shares in the company, valued at approximately $295,951,392.32. The trade was a 3.67 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the transaction, the insider now owns 82,139 shares of the company's stock, valued at $3,473,658.31. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,002 shares of company stock valued at $348,203 over the last quarter. Company insiders own 29.40% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.